Title:
ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY
Document Type and Number:
WIPO Patent Application WO/2017/011804
Kind Code:
A8
Abstract:
Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells. In some embodiments, the antigen recognized by the engineered antigen receptor is related to a tumor antigen recognized by the engineered antigen receptor.
More Like This:
Inventors:
MOHLER KENDALL M (US)
LEVITSKY HYAM I (US)
SATHER BLYTHE (US)
LEVITSKY HYAM I (US)
SATHER BLYTHE (US)
Application Number:
PCT/US2016/042647
Publication Date:
January 25, 2018
Filing Date:
July 15, 2016
Export Citation:
Assignee:
JUNO THERAPEUTICS INC (US)
International Classes:
C12N5/0783
Attorney, Agent or Firm:
POTTER, Karen et al. (US)
Download PDF: